Search

Author/Creator Pollyea, D. A.

1. P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX-BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE. (23rd June 2022)

Authors:
Wolach, O.; Garcia, J. S.; Vachhani, P.; Zeidner, J.; Lai, C.; Moshe, Y.; Xavier, M.; Lee, S.; Zuckerman, T.; Pollyea, D. A.; Abedin, S.; Chen, E. C.; Bathini, S.; Edwards, W.; Bui, C. N.; Cheng, W. W.-H.; Svensson, A.; Guérin, A.; Maitland, J.; Ma, E.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
418
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P570: REAL-WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA. (23rd June 2022)

Authors:
Zeidan, A. M.; Pollyea, D. A.; Borate, U.; Vasconcelos, A.; Potluri, R.; Rotter, D.; Kiendrebeogo, Z.; Gaugler, L.; Bonifacio, G.; Prebet, T.; Chen, C.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
469
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS. (23rd June 2022)

Authors:
Sallman, D. A.; Al Malki, M. M.; Asch, A. S.; Wang, E. S.; Jurcic, J. G.; Bradley, T. J.; Flinn, I. W.; Pollyea, D. A.; Kambhampati, S. N.; Tanaka, T. N.; Zeidner, J. F.; Garcia-Manero, G.; Jeyakumar, D.; Gu, L.; Tan, A.; Chao, M.; O'Hear, C.; Lal, I.; Vyas, P.; Daver, N.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
67
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search